RT Journal Article
T1 The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study.
A1 van Straalen, Kelsey R
A1 Tzellos, Thrasyvoulos
A1 Guillem, Phillipe
A1 Benhadou, Farida
A1 Cuenca-Barrales, Carlos
A1 Daxhelet, Mathilde
A1 Daoud, Mathieu
A1 Efthymiou, Ourania
A1 Giamarellos-Bourboulis, Evangelos J
A1 Jemec, Gregor B E
A1 Katoulis, Alexandros C
A1 Koenig, Anke
A1 Lazaridou, Elizabeth
A1 Marzano, Angelo V
A1 Matusiak, Łucas
A1 Molina-Leyva, Alejandro
A1 Moltrasio, Chiara
A1 Pinter, Andreas
A1 Potenza, Concetta
A1 Romaní, Jorge
A1 Saunte, Ditte M
A1 Skroza, Nevena
A1 Stergianou, Dimitra
A1 Szepietowski, Jacek
A1 Trigoni, Anastasia
A1 Vilarrasa, Eva
A1 van der Zee, Hessel H
K1 acne inversa
K1 antibiotics
K1 clindamycin
K1 doxycycline
K1 efficacy
K1 guideline
K1 minocycline
K1 outcome
K1 rifampicin
K1 tetracycline
K1 therapy
K1 treatment
AB Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes. To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin. A prospective, international cohort study performed between October 2018 and August 2019. In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P  Cohort study. Respectively, 23.9% and 19.4% of patients had to be excluded from the HiSCR analysis for the tetracycline and combination therapy group because of a low abscess and nodule count at baseline. This study shows significant efficacy of both tetracycline treatment and clindamycin and rifampicin combination therapy after 12 weeks in patients with hidradenitis suppurativa. No significant differences in efficacy were observed between the 2 treatments, regardless of disease severity.
YR 2021
FD 2021-01-20
LK http://hdl.handle.net/10668/17028
UL http://hdl.handle.net/10668/17028
LA en
DS RISalud
RD Apr 8, 2025